7 December 2021

Unique recombinant APRIL antibody confers atheroprotection

AdipoGen Life Sciences offers the potent anti-APRIL (mouse) mAb (Clone Apry-1-1) blocking antibody promoting the binding of APRIL to HSPGs to reduce experimental atherosclerosis and provide atheroprotection.


A recent study reports that APRIL confers atheroprotection by binding to heparan sulfate chains of heparan-sulfate proteoglycan 2 (HSPG2), which limits the retention of low-density lipoproteins, accumulation of macrophages and formation of necrotic cores. In this study, they use AdipoGen’s specific anti-APRIL (mouse) antibody (Apry-1-1) that promotes the binding of APRIL to HSPGs to reduce experimental atherosclerosis. They also observe that serum levels of a specific form of human APRIL that binds to HSPGs (termed non-canonical APRIL), are associated with long-term cardiovascular mortality in patients with atherosclerosis [ref. 1].

anti-APRIL (mouse), mAb (rec.) (blocking) (Apry-1-1)

AdipoGen Life Sciences’ anti-APRIL (mouse), mAb (rec.) (blocking) (Apry-1-1) (Cat. No. AG-27B-0001) is a recombinant monoclonal antibody that recognizes mouse APRIL and works specifically in IP and Functional Application. The antibody inhibits mouse APRIL binding to BCMA and TACI. It is highly potent in blocking mouse APRIL in vitro and in vivo. In addition it promotes the binding of APRIL to HSPGs and confers atheroprotection. The antibody is available with or without preservatives.

Figure: Binding of APRIL (mouse) to BCMA is inhibited by anti-APRIL (mouse), mAb (rec.) (blocking) (APRY-1-1) (Prod. No. AG-27B-0001).
Method: BCMA:Fc was coated on an ELISA plate at 1μg/ml. anti-APRIL (mouse) mAb (rec.) (blocking) (APRY-1-1) or an unrelated mAb (recombinant) (Negative control) were added (starting at 50μg/ml with a twofold serial dilution) together with 0.1μg/ml of MultimericAPRIL (mouse). After incubation for 1h at RT, the MultimericAPRIL (mouse) binding was detected using an anti-FLAG® antibody (HRP). The percentage of binding is shown.

References

  1. Tsiantoulas D, Eslami M, Obermayer G, et al. APRIL limits atherosclerosis by binding to heparan sulfate proteoglycans. Nature. 2021;597(7874):92-96.

Unique recombinant APRIL antibody confers atheroprotection

Related articles

Newsletter for researchers

We gladly support you by keeping you updated on our latest products and the developments around our services.

Need help? Contact our technical support
Contact